Symbols / CELZ Stock $2.30 +2.68% Creative Medical Technology Holdings, Inc.

Healthcare • Biotechnology • United States • NCM
CELZ (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Timothy Warbington
Exch · Country NCM · United States
Market Cap 8.50M
Enterprise Value 1.32M
Income -6.00M
Sales 6.00K
FCF (ttm) -3.75M
Book/sh 2.03
Cash/sh 1.95
Employees 4
Insider 10d —
IPO Nov 06, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.70
PEG —
P/S 1,417.06
P/B 1.13
P/C —
EV/EBITDA -0.22
EV/Sales 219.73
Quick Ratio 25.30
Current Ratio 25.97
Debt/Eq 0.19
LT Debt/Eq —
EPS (ttm) -2.52
EPS next Y -1.35
EPS Growth —
Revenue Growth 0.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-20
Earnings (prior) 2026-03-20
ROA -53.03%
ROE -86.47%
ROIC —
Gross Margin 63.43%
Oper. Margin -648.59%
Profit Margin 0.00%
Shs Outstand 3.70M
Shs Float 3.43M
Insider Own 0.95%
Instit Own 7.15%
Short Float 4.28%
Short Ratio 2.46
Short Interest 156.76K
52W High 6.25
vs 52W High -63.20%
52W Low 1.50
vs 52W Low 52.93%
Beta 1.99
Impl. Vol. —
Rel Volume 0.46
Avg Volume 41.42K
Volume 19.21K
Target (mean) $20.00
Tgt Median $20.00
Tgt Low $20.00
Tgt High $20.00
# Analysts 1
Recom None
Prev Close $2.24
Price $2.30
Change 2.68%
About

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$20.00
Mean price target
2. Current target
$2.30
Latest analyst target
3. DCF / Fair value
$-18.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.30
Low
$20.00
High
$20.00
Mean
$20.00
News
RSS: Latest CELZ news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-02-19 FINGER MICHAEL H. Director — 1,500 $5.00 $8,062
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.01
-45.45%
0.01
+22.22%
0.01
-89.84%
0.09
Operating Revenue
0.01
-45.45%
0.01
+22.22%
0.01
-89.84%
0.09
Cost Of Revenue
0.00
-50.14%
0.00
+22.22%
0.00
-87.36%
0.03
Reconciled Cost Of Revenue
0.00
-50.14%
0.00
+22.22%
0.00
-87.36%
0.03
Gross Profit
0.00
-42.33%
0.01
+22.22%
0.01
-91.02%
0.06
Operating Expense
6.15
+6.89%
5.75
+2.22%
5.63
-45.41%
10.30
Research And Development
2.26
-5.87%
2.40
+21.83%
1.97
-68.56%
6.27
Selling General And Administration
3.76
+16.18%
3.24
-9.02%
3.56
-9.72%
3.94
Total Expenses
6.15
+6.85%
5.75
+2.23%
5.63
-45.52%
10.33
Operating Income
-6.14
-6.95%
-5.74
-2.20%
-5.62
+45.14%
-10.24
Total Operating Income As Reported
-6.14
-6.95%
-5.74
-2.20%
-5.62
+45.14%
-10.24
EBITDA
-6.02
-6.85%
-5.63
-1.95%
-5.53
+45.57%
-10.15
Normalized EBITDA
-6.02
-6.85%
-5.63
-1.95%
-5.53
+45.57%
-10.15
Reconciled Depreciation
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
EBIT
-6.14
-6.95%
-5.74
-2.20%
-5.62
+45.14%
-10.24
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Pretax Income
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Net Non Operating Interest Income Expense
0.15
-40.97%
0.25
-24.94%
0.33
+232.47%
0.10
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
0.15
-40.97%
0.25
-24.94%
0.33
+232.47%
0.10
Interest Expense
—
—
—
0.00
Interest Income Non Operating
0.15
-40.97%
0.25
-24.94%
0.33
+232.47%
0.10
Interest Income
0.15
-40.97%
0.25
-24.94%
0.33
+232.47%
0.10
Other Income Expense
—
—
—
—
Gain On Sale Of Security
—
—
—
—
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Net Income From Continuing Operation Net Minority Interest
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Net Income From Continuing And Discontinued Operation
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Net Income Continuous Operations
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Normalized Income
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Net Income Common Stockholders
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Diluted EPS
—
-3.71
+1.33%
-3.76
+59.48%
-9.28
Basic EPS
—
-3.71
+1.33%
-3.76
+59.48%
-9.28
Basic Average Shares
—
1.48
+5.17%
1.41
+28.76%
1.09
Diluted Average Shares
—
1.48
+5.17%
1.41
+28.76%
1.09
Diluted NI Availto Com Stockholders
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Amortization
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Amortization Of Intangibles Income Statement
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Depreciation Amortization Depletion Income Statement
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Depreciation And Amortization In Income Statement
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
7.81
+17.10%
6.67
-37.76%
10.72
Current Assets
7.40
+20.60%
6.14
-40.27%
10.27
Cash Cash Equivalents And Short Term Investments
7.21
+21.34%
5.94
-40.52%
9.99
Cash And Cash Equivalents
7.21
+21.34%
5.94
+71.35%
3.47
Cash Equivalents
—
—
—
Cash Financial
7.21
+21.34%
5.94
+71.35%
3.47
Other Short Term Investments
—
0.00
-100.00%
6.52
Receivables
0.05
0.00
—
Accounts Receivable
—
—
—
Inventory
0.00
-100.00%
0.00
-66.73%
0.01
Prepaid Assets
—
—
—
Other Current Assets
0.14
-27.97%
0.19
-30.49%
0.28
Total Non Current Assets
0.41
-23.10%
0.53
+20.16%
0.44
Goodwill And Other Intangible Assets
0.41
-23.25%
0.53
+20.31%
0.44
Other Intangible Assets
0.41
-23.25%
0.53
+20.31%
0.44
Other Non Current Assets
0.00
+0.00%
0.00
+0.00%
0.00
Total Liabilities Net Minority Interest
0.28
-13.05%
0.33
-11.78%
0.37
Current Liabilities
0.28
-13.05%
0.33
-11.78%
0.37
Payables And Accrued Expenses
0.28
-13.05%
0.33
-11.78%
0.37
Payables
0.28
-0.99%
0.29
-13.20%
0.33
Accounts Payable
0.27
-1.04%
0.27
-13.79%
0.32
Current Accrued Expenses
0.00
-100.00%
0.04
+0.00%
0.04
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
Stockholders Equity
7.51
+18.50%
6.34
-38.69%
10.34
Common Stock Equity
7.51
+18.50%
6.34
-38.69%
10.34
Capital Stock
0.00
+79.76%
0.00
+22.22%
0.00
Common Stock
0.00
+79.76%
0.00
+22.22%
0.00
Preferred Stock
0.00
0.00
0.00
Share Issued
3.70
+111.71%
1.75
+22.17%
1.43
Ordinary Shares Number
3.70
+111.43%
1.75
+27.29%
1.37
Treasury Shares Number
0.01
0.00
-100.00%
0.06
Additional Paid In Capital
78.11
+10.12%
70.93
+1.75%
69.71
Retained Earnings
-70.59
-9.28%
-64.59
-9.30%
-59.10
Treasury Stock
0.01
0.00
-100.00%
0.27
Minority Interest
0.01
0.00
—
Total Equity Gross Minority Interest
7.52
+18.66%
6.34
-38.69%
10.34
Total Capitalization
7.51
+18.50%
6.34
-38.69%
10.34
Working Capital
7.11
+22.50%
5.81
-41.33%
9.90
Invested Capital
7.51
+18.50%
6.34
-38.69%
10.34
Net Tangible Assets
7.11
+22.31%
5.81
-41.32%
9.90
Tangible Book Value
7.11
+22.31%
5.81
-41.32%
9.90
Dueto Related Parties Current
0.01
+0.00%
0.01
+0.00%
0.01
Notes Receivable
0.05
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.86
-10.47%
-5.30
+33.96%
-8.03
-2.96%
-7.80
Cash Flow From Continuing Operating Activities
-5.86
-10.47%
-5.30
+33.96%
-8.03
-2.96%
-7.80
Net Income From Continuing Operations
-6.00
-9.13%
-5.49
-3.91%
-5.29
+47.88%
-10.14
Depreciation Amortization Depletion
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Amortization Cash Flow
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Depreciation And Amortization
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Amortization Of Intangibles
0.12
+11.66%
0.11
+16.78%
0.09
+2.71%
0.09
Other Non Cash Items
-0.00
—
—
—
Stock Based Compensation
0.00
-90.49%
0.04
+0.00%
0.04
-46.69%
0.07
Provisionand Write Offof Assets
—
—
—
0.00
Operating Gains Losses
—
—
-0.03
—
Gain Loss On Investment Securities
—
—
-0.03
—
Change In Working Capital
0.01
-70.43%
0.05
+101.59%
-2.84
-229.83%
2.19
Change In Receivables
—
—
0.00
-100.00%
0.00
Changes In Account Receivables
—
—
0.00
-100.00%
0.00
Change In Inventory
0.00
-50.14%
0.00
+22.22%
0.00
+435.71%
0.00
Change In Prepaid Assets
0.05
-36.24%
0.08
-21.87%
0.11
+132.00%
-0.34
Change In Payables And Accrued Expense
-0.04
+2.48%
-0.04
+98.51%
-2.95
-217.02%
2.52
Change In Accrued Expense
-0.04
0.00
0.00
-100.00%
0.02
Change In Payable
-0.00
+93.52%
-0.04
+98.51%
-2.95
-217.74%
2.51
Change In Account Payable
-0.00
+93.52%
-0.04
+98.51%
-2.95
-217.74%
2.51
Change In Other Current Liabilities
0.00
0.00
—
—
Investing Cash Flow
-0.05
-100.80%
6.32
+83.45%
3.45
+134.18%
-10.08
Cash Flow From Continuing Investing Activities
-0.05
-100.80%
6.32
+83.45%
3.45
+134.18%
-10.08
Capital Expenditure
—
-0.20
-100.00%
-0.10
—
Net Investment Purchase And Sale
0.00
-100.00%
6.52
+83.92%
3.55
+135.18%
-10.08
Purchase Of Investment
—
0.00
+100.00%
-22.85
-126.77%
-10.08
Sale Of Investment
0.00
-100.00%
6.52
-75.30%
26.40
0.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.20
-100.00%
-0.10
0.00
Purchase Of Intangibles
0.00
+100.00%
-0.20
-100.00%
-0.10
0.00
Net Other Investing Changes
-0.05
—
—
—
Financing Cash Flow
7.17
+393.23%
1.45
+636.86%
-0.27
-101.75%
15.47
Cash Flow From Continuing Financing Activities
7.17
+393.23%
1.45
+636.86%
-0.27
-101.75%
15.47
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
7.16
+392.57%
1.45
+636.82%
-0.27
-101.75%
15.47
Common Stock Payments
-0.01
+94.28%
-0.17
+35.43%
-0.27
0.00
Repurchase Of Capital Stock
-0.01
+94.28%
-0.17
+35.43%
-0.27
0.00
Proceeds From Stock Option Exercised
—
—
0.00
-100.00%
0.00
Net Other Financing Charges
0.01
—
—
—
Changes In Cash
1.27
-48.75%
2.47
+150.96%
-4.85
-101.95%
-2.40
Beginning Cash Position
5.94
+71.35%
3.47
-58.33%
8.32
-22.41%
10.72
End Cash Position
7.21
+21.34%
5.94
+71.35%
3.47
-58.33%
8.32
Free Cash Flow
-5.86
-6.46%
-5.50
+32.32%
-8.13
-4.24%
-7.80
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
7.17
+340.30%
1.63
0.00
-100.00%
15.47
Issuance Of Capital Stock
7.17
+340.27%
1.63
0.00
-100.00%
15.47
Net Preferred Stock Issuance
0.00
-100.00%
0.00
0.00
0.00
Preferred Stock Issuance
0.00
-100.00%
0.00
0.00
0.00
Preferred Stock Payments
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category